Orion Oyj B Cash Flow Conversion Efficiency
Orion Oyj B cash flow conversion efficiency. Based on the latest financial reports, Orion Oyj B (ORNBV) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€79.50 Million ≈ $92.94 Million USD) by net assets (€919.60 Million ≈ $1.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Orion Oyj B (2000–2024)
Cash flow conversion efficiency of Orion Oyj B from 2000 to 2024. This chart illustrates how Orion Oyj B's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ORNBV stock price for real-time trading data and today's change.
Orion Oyj B Cash Flow Conversion Ratio Explained
Orion Oyj B cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Orion Oyj B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orion Oyj B ranked by their cash flow conversion efficiency. Also see Orion Oyj B market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
N/A |
|
Frontline Ltd
NYSE:FRO
|
0.113x |
|
Ramsay Health Care Ltd
AU:RHC
|
0.062x |
|
Ivanhoe Mines Ltd.
TO:IVN
|
-0.006x |
|
Primerica Inc
NYSE:PRI
|
0.062x |
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
0.047x |
|
Biomerieux SA
PA:BIM
|
0.115x |
|
HudBay Minerals Inc
TO:HBM
|
0.052x |
Annual Cash Flow Conversion Efficiency for Orion Oyj B (2000–2024)
The table below shows the annual cash flow conversion efficiency of Orion Oyj B from 2000 to 2024. Review Orion Oyj B free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
€293.40 Million ≈ $343.02 Million |
0.292x | +118.37% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
€119.00 Million ≈ $139.12 Million |
0.134x | -72.05% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
€434.40 Million ≈ $507.86 Million |
0.478x | +65.86% |
| 2021-12-31 | €747.90 Million ≈ $874.37 Million |
€215.70 Million ≈ $252.18 Million |
0.288x | -29.48% |
| 2020-12-31 | €731.30 Million ≈ $854.97 Million |
€299.10 Million ≈ $349.68 Million |
0.409x | +17.72% |
| 2019-12-31 | €779.40 Million ≈ $911.20 Million |
€270.80 Million ≈ $316.59 Million |
0.347x | +16.33% |
| 2018-12-31 | €773.10 Million ≈ $903.84 Million |
€230.90 Million ≈ $269.95 Million |
0.299x | -11.12% |
| 2017-12-31 | €679.70 Million ≈ $794.64 Million |
€228.40 Million ≈ $267.02 Million |
0.336x | -13.52% |
| 2016-12-31 | €641.10 Million ≈ $749.51 Million |
€249.10 Million ≈ $291.22 Million |
0.389x | -9.32% |
| 2015-12-31 | €594.90 Million ≈ $695.50 Million |
€254.90 Million ≈ $298.00 Million |
0.428x | -25.64% |
| 2014-12-31 | €514.90 Million ≈ $601.97 Million |
€296.70 Million ≈ $346.87 Million |
0.576x | +37.60% |
| 2013-12-31 | €513.90 Million ≈ $600.80 Million |
€215.20 Million ≈ $251.59 Million |
0.419x | -3.14% |
| 2012-12-31 | €511.20 Million ≈ $597.65 Million |
€221.00 Million ≈ $258.37 Million |
0.432x | +8.68% |
| 2011-12-31 | €500.00 Million ≈ $584.55 Million |
€198.90 Million ≈ $232.54 Million |
0.398x | -11.08% |
| 2010-12-31 | €467.40 Million ≈ $546.44 Million |
€209.10 Million ≈ $244.46 Million |
0.447x | -3.99% |
| 2009-12-31 | €439.10 Million ≈ $513.35 Million |
€204.60 Million ≈ $239.20 Million |
0.466x | +35.07% |
| 2008-12-31 | €418.60 Million ≈ $489.39 Million |
€144.40 Million ≈ $168.82 Million |
0.345x | +2.25% |
| 2007-12-31 | €447.30 Million ≈ $522.94 Million |
€150.90 Million ≈ $176.42 Million |
0.337x | +83.36% |
| 2006-12-31 | €443.50 Million ≈ $518.50 Million |
€81.60 Million ≈ $95.40 Million |
0.184x | -38.23% |
| 2005-12-31 | €581.80 Million ≈ $680.19 Million |
€173.30 Million ≈ $202.61 Million |
0.298x | -22.89% |
| 2004-12-31 | €479.70 Million ≈ $560.82 Million |
€185.30 Million ≈ $216.64 Million |
0.386x | +111.66% |
| 2003-12-31 | €597.80 Million ≈ $698.89 Million |
€109.10 Million ≈ $127.55 Million |
0.183x | +17.05% |
| 2002-12-31 | €685.60 Million ≈ $801.54 Million |
€106.90 Million ≈ $124.98 Million |
0.156x | -6.00% |
| 2001-12-31 | €677.60 Million ≈ $792.19 Million |
€112.40 Million ≈ $131.41 Million |
0.166x | +12.40% |
| 2000-12-31 | €668.80 Million ≈ $781.90 Million |
€98.70 Million ≈ $115.39 Million |
0.148x | -- |
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more